Elation Health, a clinical-first technology company driving innovation in primary care, today shared the results of its latest survey of 100 primary care physicians (PCPs). The survey provides valuable insights into the adoption and impact of artificial intelligence (AI) in…
Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) for the first-line…
HCA Healthcare, one of the nation’s leading healthcare providers, has been named a Best for Vets Employer by Military Times for the fifth consecutive year, in recognition of its ongoing efforts to recruit, mentor, and retain U.S. service members. Since…
Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, today announced new data demonstrating the enhanced capabilities of its AI-powered solution, vMap, for improving cardiac arrhythmia treatment. The data, to be presented at the American Heart Association (AHA) Scientific…
Cofactor Genomics, Inc., a clinical-stage company focused on bridging the precision medicine gap through RNA decoding, today announced the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic test designed to predict response to immune checkpoint inhibitors (ICI) in patients with…
Synthekine Inc., a company specializing in engineered cytokine therapeutics, today announced that promising preclinical results from its murine STK-009 + SYNCAR-001 program will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. The data highlights…
Exact Sciences Corp. (NASDAQ: EXAS), a leader in cancer screening and diagnostic tests, will present three key abstracts at the American Association for Cancer Research (AACR) Special Conference on Liquid Biopsy, taking place November 13-16, 2024, in San Diego, CA.…
Certinal eSign, a leader in Digital Transaction Management, has strengthened its strategic partnership with Bumrungrad International Hospital, a globally recognized healthcare provider, to revolutionize patient registration and data management. This expanded collaboration will drive greater efficiencies, improve security, and transform…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe ischemic diseases, today announced that the first patient has been dosed in its investigator-sponsored Phase 2 trial of DM199 for preeclampsia (PE). The company…
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on using patients’ own biology to treat rare diseases, presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem) clinical trial at the 53rd Child Neurology…
